Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Zurich
ClinicalTrials.gov Identifier:
NCT00492895
First received: June 19, 2007
Last updated: January 28, 2013
Last verified: January 2013
  Purpose

Photosensitivity of the skin to UVA and UVB will be determined


Condition Intervention Phase
Skin Cancer
Drug: Discontinuation of Azathioprin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Photosensitivity of the skin to UVA and UVB [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment: 25
Study Start Date: June 2007
Study Completion Date: March 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A
one arm only. Crossover study
Drug: Discontinuation of Azathioprin
Discontinuation of Azathioprin
Other Name: Discontinuation of Azathioprin

Detailed Description:

Photosensitivity of the skin to UVA and UVB in renal transplant recipients with and without azathioprine will be determined. Azathioprine will be discontinued and photosensitivity determined after a wash-out period of three months

  • Trial with medicinal product
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • Renal transplant recipients under azathioprin

Exclusion criteria:

  • Treatment with Prograf (Tacrolimus)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00492895

Locations
Switzerland
Clinic for Dermatology, University Hospital of Zurich
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: Günther Hofbauer, M.D UniversitaetsSpital Zuerich
  More Information

Publications:
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT00492895     History of Changes
Other Study ID Numbers: 2007DR2040
Study First Received: June 19, 2007
Last Updated: January 28, 2013
Health Authority: Switzerland: Swissmedic

ClinicalTrials.gov processed this record on September 30, 2014